Tetra Bio-Pharma Engaged Alpha Bronze LLC as Investor Relations and Public Relations Firm
Tetra Bio-Pharma Inc. (TSX-V: TBP) (OTCQB: TBPMF), is a leader in cannabinoid-derived drug discovery and development. The company announced that it has engaged Alpha Bronze LLC., by its principal, Mr. Pascal Nigen, an investor relations, management consulting and financial communications firm to implement and execute a comprehensive investor relations and communications program.
Based in New York and founded in 2013, Alpha Bronze is an Investor Relations firm, offering a full suite of services – road shows, access to Investor Conferences, Press Releases and assistance with research coverage. They’re dedicated to the delivery of top-tier strategic advisory services that encompass investor and stakeholder relations, capital markets navigation, corporate communications for emerging growth companies. Their team has extensive experience with life sciences, cannabis, tech, clean-tech and resources companies around the globe. As an aggregation, distribution, and engagement platform, Alpha Bronze reaches thousands of individual, retail and institutional investors in its proprietary and extensive distribution network.
Tetra Bio-Pharma is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.
“I am very pleased and excited to have engaged Alpha Bronze as our new IR firm. They have demonstrated in a recent mandate provided to them that they have an excellent investors network and know-how of financial communications for the Health Care sector in the United States. In addition, their level of engagement in supporting their clients will be key for Tetra Bio-Pharma moving forward with its business execution” stated Sylvain Chretien, the newly appointed President of Tetra Bio-Pharma. “I would like to thank EnergiPR and LifeSci for their support and contributions to Tetra.”
The agreement for the engagement of Alpha Bronze commenced on March 1, 2020 for a term of 12 months. Alpha Bronze will be paid fees of US$10,000 per month for its services, and received 200,000 stock options, for a period of 3 years with 50,000 options vesting immediately, 50,000 options vesting on May 18, 2020, and the remaining 100,000 options vesting over conditional milestones. The options have an exercise price of $0.42.
Tetra has provided notices of termination to LifeSci Advisors and LifeSci Public Relations as well as EnergiPR as part of the transition in investor relations and public relations services to Alpha Bronze. These terminations account for a net saving for approximately US$38,000 per month.